Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most scientific/mechanistic points (GnRH antagonist; estradiol/progesterone decrease) and several safety claims (bone loss risk; suicidal ideation/behavior with mood monitoring) are supported by the provided label sections. However, several side-effect claims (headache, nausea, hot flashes) are not supported by the provided label text, and the labeling-compatible description of endocrine effects and symptom changes (meal menstrual bleeding changes; bone loss is dose/duration dependent) is partially overstated. Overall alignment is mixed due to multiple unsupported adverse-effect items and some imprecision.
Category Scores
Accurate Statements
Orilissa (elagolix) is a medication used to manage pain associated with endometriosis.
Label: 'ORILISSA is indicated for the management of moderate to severe pain associated with endometriosis.' (Indications and Usage)
Orilissa functions by suppressing the production of key hormones that fuel the growth of endometrial tissue.
Label mechanism: 'GnRH receptor antagonist… leading to decreased blood concentrations of estradiol and progesterone.' (Clinical Pharmacology 12.1). Label does not explicitly say 'production' or 'fuel growth' phrasing; but the suppression of estradiol/progesterone is supported.
Orilissa is a gonadotropin-releasing hormone (GnRH) antagonist.
Label: 'ORILISSA is a GnRH receptor antagonist…' (Clinical Pharmacology 12.1)
Orilissa binds to GnRH receptors in the pituitary gland.
Label: GnRH receptor antagonist; also describes mechanism leading to decreased estradiol/progesterone (Clinical Pharmacology 12.1). Pituitary binding is consistent with antagonist mechanism as described.
By binding to pituitary GnRH receptors, Orilissa prevents the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Label mechanism supports GnRH receptor antagonist activity leading to decreased estradiol/progesterone (Clinical Pharmacology 12.1). The specific LH/FSH prevention mechanism is not explicitly quoted in the provided label text but is consistent with the GnRH antagonist description.
LH and FSH are essential for the ovaries to produce estrogen.
Not explicitly stated in the provided label excerpts.
Because Orilissa lowers estrogen levels, it can lead to bone density loss.
Label: 'ORILISSA causes a dose-dependent decrease in bone mineral density (BMD).' (Warnings and Precautions 5.1). Mechanism includes decreased estradiol/progesterone (Clinical Pharmacology 12.1).
Orilissa use may be associated with suicidal thoughts or behaviors.
Label: 'Suicidal ideation and behavior… occurred in subjects treated with ORILISSA…' (Warnings and Precautions 5.3)
Patients taking Orilissa should be monitored for changes in mood or behavior.
Label: 'Promptly evaluate patients with depressive symptoms… Reevaluate the benefits and risks of continuing ORILISSA if such events occur.' (Warnings and Precautions 5.3)
Elagolix has been approved in combination with other medications to manage heavy menstrual bleeding associated with uterine fibroids.
Not determinable from the provided label excerpts (label provided is for Orilissa endometriosis pain).
Orilissa is an oral GnRH antagonist.
Label excerpts confirm tablets (Dosage Forms and Strengths: '150 mg tablets' and '200 mg tablets') and mechanism 'GnRH receptor antagonist' (Clinical Pharmacology 12.1).
Unsupported Statements
Common side effects of Orilissa include headache.
The provided label excerpts do not list headache among adverse reactions.
Common side effects of Orilissa include nausea.
The provided label excerpts do not list nausea among adverse reactions.
Common side effects of Orilissa include hot flashes.
The provided label excerpts do not list hot flashes among adverse reactions.
By lowering estrogen levels, Orilissa helps to shrink and slow the growth of endometrial implants.
The provided excerpts support decreased estradiol/progesterone and management of endometriosis-associated pain, but do not explicitly claim implant shrinkage or slowed growth.
Shrinking and slowing the growth of endometrial implants helps to reduce pain.
The provided excerpts do not explicitly connect implant shrinkage/growth slowing to pain reduction.
Elagolix has been approved in combination with other medications to manage heavy menstrual bleeding associated with uterine fibroids.
Not supported by the provided Orilissa label excerpts (which focus on endometriosis-associated pain).
LH and FSH are essential for the ovaries to produce estrogen.
Not explicitly stated in the provided label excerpts.
Contradictions
Low
AI Statement
By lowering estrogen levels, Orilissa helps to shrink and slow the growth of endometrial implants.
Label Reference
No contradiction identified in provided excerpts; this is treated as unsupported due to absence of explicit support.
Important Omissions
The label-based contraindication/usage constraints related to duration limits for bone loss (e.g., maximum treatment duration by dose/coexisting condition) are not addressed in the claims list.
Importance:
Moderate
The label requires non-hormonal contraception during treatment and for 28 days after discontinuation; this is not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple safety-relevant items (bone loss and suicidal ideation/mood evaluation) are aligned with provided label excerpts. However, several adverse-effect assertions (headache, nausea, hot flashes) are unsupported by the provided label text, and key label-directed risk mitigation details (duration limits and contraception guidance) were omitted, which could affect safe and accurate information sharing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims (notably specific 'common side effects' and implant shrinkage/growth effects; plus fibroid combination approval) are not supported by the provided label excerpts.
Suggested Improvement
Limit statements to label-supported items in the provided text: endometriosis pain indication; GnRH antagonist mechanism leading to decreased estradiol/progesterone; bone loss warnings; suicidal ideation/behavior and evaluation of depressive symptoms. Remove or rephrase unsupported adverse-effect and fibroid-combination approval claims unless the exact label text for those topics is provided.